Jacobs selected by Sanofi to deliver new insulin manufacturing facility in Germany
Business Wire•19/11/2026•03:30 ET
0
Key Highlights
- ➤Jacobs (J) selected as EPCM partner for Sanofi’s new Frankfurt insulin facility
- ➤Frankfurt facility will produce multiple insulin products and strengthen supply reliability
- ➤Jacobs will provide design, procurement, construction management and commissioning services
- ➤Jacobs has approximately $12 billion in annual revenue and 47,000 employees
Expert Statements
Sean Sommer, Executive Vice President of Jacobs
“Our life sciences legacy began in 1943, when our founder, Dr. Joe Jacobs, was part of the team that enabled the first commercial-scale production of penicillin. More than 80 years later, we continue to deliver the advanced manufacturing facilities behind some of the world's most important therapies.”
Jacobs selected by Sanofi to deliver new insulin manufacturing facility in Germany
Project modernizes insulin manufacturing and strengthens supply resilience
Get started
Create a free account to read the full story.
